| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 03/27/2008 | WO2008035908A1 Therapeutic cell medicine comprising skin tissue derived stem cell |
| 03/27/2008 | WO2008035823A1 Cell death inhibitor |
| 03/27/2008 | WO2008035757A1 Jelly-like food containing ubiquinol |
| 03/27/2008 | WO2008035604A1 Composition for amelioration of brain function |
| 03/27/2008 | WO2008035023A1 Polymorphs of rimonabant |
| 03/27/2008 | WO2008035001A2 Composition for the treatment of amyotrophic lateral sclerosis |
| 03/27/2008 | WO2008034974A1 2-ARYL-6-PHENYLIMIDAZO[1,2-α]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF |
| 03/27/2008 | WO2008034863A2 Sulfonylpyrazoline carboxamidine derivatives as 5-ht6 antagonists |
| 03/27/2008 | WO2008034815A1 Combination of nmda- receptor ligand and a compound with 5-ht6 receptor affinity |
| 03/27/2008 | WO2008034735A2 4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]diazepine derivatives |
| 03/27/2008 | WO2008034628A1 Aripiprazole hemifumarate and process for its preparation |
| 03/27/2008 | WO2008034244A1 The combination of a cyclohexanehexol and a nsaid for the treatment of neurodegenerative diseases |
| 03/27/2008 | WO2008034202A2 Use of ivermectin and derivates thereof for the treatment of amyotrophic lateral sclerosis |
| 03/27/2008 | WO2008034161A1 Neuroprotective peptide inhibitors of ap-1 signaling and uses therefor |
| 03/27/2008 | WO2008005869A3 Infant formulas for early brain development |
| 03/27/2008 | WO2008000469A3 Nicotinic agonists selective for the alpha7 receptor subtype, the process for the preparation thereof and pharmaceutical compositions therefrom |
| 03/27/2008 | WO2008000430A3 Alphanizomenon flos aquae preparation, extracts and purified components thereof for the treatment of neurological, neurodegenerative and mood disorders |
| 03/27/2008 | WO2008000070B1 Glycyrrhetinic acid derivatives |
| 03/27/2008 | WO2007147497A3 Use of a disintegrin-like and metalloproteinase with thrombospondin type 1 motif (adamts1) as a therapeutic or diagnostic target |
| 03/27/2008 | WO2007139984A3 Duloxetine hcl polymorphs |
| 03/27/2008 | WO2007136668A9 N-benzoyl-and n-benzylpyrrolidin-3-ylamines as histamine-3 antagonists |
| 03/27/2008 | WO2007135530A3 Pharmaceutically & veterinarily suitable salt |
| 03/27/2008 | WO2007132179A3 Therapeutics comprising pyridinium derivatives |
| 03/27/2008 | WO2007103370A3 Quinazoline derivatives as phosphodiesterase 10 inhibitors |
| 03/27/2008 | WO2007045663A3 Combination of an ati receptor antagonist and a np inhibitor fro treating ia hypertension and heartfailure |
| 03/27/2008 | US20080076943 4-(Hydroxymethyl)-2,6-dimethoxyphenylboronic acid chemical intermediate for preparing corticotropin-releasing factor receptor antagonists |
| 03/27/2008 | US20080076918 Quinoxaline compounds |
| 03/27/2008 | US20080076825 with levodopa and decarboxylase inhibitors; Parkinson's syndrome; from Knoevenagel condensation of 3,4-dihydroxy-5-nitro-benzaldehyde and N,N-diethyl-2-cyanoacetamide |
| 03/27/2008 | US20080076820 Improving the activities of daily living in a post-stroke patient by administering nefiracetam or its salts initiated within 12 months of stroke; nefiracetam possesses neurotrophic activity |
| 03/27/2008 | US20080076817 Neurotrophic N-glyoxyl-prolyl ester compounds e.g. 3-phenyl-1-propyl (2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-pyrrolidinecarboxylate; non-immunosuppressive; side effect reduction; neurodegenerative diseases |
| 03/27/2008 | US20080076815 Sulfonamide or sulfonimide functional indazole or indole compounds such as N-[3-[2-[2-(3-methylindazol-6-yloxy)ethylamino]-1-hydryoxyethyl]phenyl]methanesulfonamide; diabetes, obesity, hyperlipidemia and urinary incontinence |
| 03/27/2008 | US20080076814 Hexahydro-Cyclooctyl Pyrazole Cannabinoid Modulators |
| 03/27/2008 | US20080076813 Benzene, Pyridine, and Pyridazine Derivatives |
| 03/27/2008 | US20080076805 Antagonists and/or inverse agonists of CB1; N'-[1-(3-chlorophenyl)-2-(4-chlorophenyl)ethyl]-N'-methyl-N-(2-methyl-2-[5-(trifluoromethylpyridin-2-yl)oxy]propanoyl)hydrazide for example; obesity, psychological disorders, analgesics, drug abuse, constipation, asthma, cirrhosis |
| 03/27/2008 | US20080076804 Methods for inhibiting and breaking age complex formation |
| 03/27/2008 | US20080076801 Indolylalkylpyridin-2-amines for the inhibition of beta-secretase |
| 03/27/2008 | US20080076800 Anticancer, inflammation, arthritis, angiogenesis, neurodegenerative diseases, fungal infections, malaria; Heat-shock protein 90 inhibitors; 4-(6,6-Dimethyl-4-oxo-3-methyl-4,5,6,7-tetrahydro-indazol-1-yl)-2-(3,4,5-trimethoxyanilino)-benzamide |
| 03/27/2008 | US20080076799 Piperidinic Derivatives, Pharmaceutic Compositions Containing the Same and Preparation Processes |
| 03/27/2008 | US20080076796 Methods and Compositions for the Treatment of Alcoholism and Alcohol Dependence |
| 03/27/2008 | US20080076795 1H-benzo[F]indazol-5-YL derivatives as selective glucocorticoid receptor modulators |
| 03/27/2008 | US20080076789 Transdermally deliverable opioid prodrugs, abuse-resistant compositions and methods of using opioid prodrugs |
| 03/27/2008 | US20080076788 Solid forms of (3'-chlorobiphenyl-4-yl)(1-(pyrimidin-2-yl)piperidin-4-yl)methanone and methods of their use |
| 03/27/2008 | US20080076783 Cycloalkyl Keto Piperidine Tachykinin Receptor Antagonists |
| 03/27/2008 | US20080076778 PARP (poly-ADP ribose polymerase); drug screening; computer networks |
| 03/27/2008 | US20080076775 3-(2-alkoxycarbonyl-3-indolyl)-3-oxo-propionic acid ester or propionamide intermediates: methyl 3-[6-fluoro-2-(methoxycarbonyl)-1-methyl-1H-indol-3-yl]-3-oxopropanoate; peripheral neuropathy, Parkinson's disease, Alzheimer's disease |
| 03/27/2008 | US20080076769 Norvaline Derivative and Method for Preparation Thereof |
| 03/27/2008 | US20080076765 4aRS,11bRS)-4-propyl-3,4,4a,5,6,8,9,11b-octahydroisoindolo[5,6-h][1,4]benzoxazin-10(2H)-one or salts useful in the treatment of disorders of CNS that involve the dopaminergic system: Parkinson's disease, hyperprolactinaemia, sexual dysfunction, depression, anxiety, Alzheimer's/neurodegenerative disease |
| 03/27/2008 | US20080076761 Pharmaceutical compositions of clonazepam and method of use thereof |
| 03/27/2008 | US20080076759 Therapeutic Heterocyclic Compounds 507 |
| 03/27/2008 | US20080076758 1S,4S)-2-((2-(1H-indazol-4-yl)-4- morpholinothieno[3,2-d]pyrirnidin-6- yl)methyl)-5-methylsulfonyl-2,5- diaza-bicyclo[2.2.1]heptane; 2-(6-fluoropyridin-3-yl)-6-((4- methylsulfonylpiperazin-1-yl)methyl)-4- morpholinothieno[3,2-d]pyrimidine; treats cancer mediated by pik3 kinase; enzyme inhibitors |
| 03/27/2008 | US20080076754 Substituted spiroheterocycles |
| 03/27/2008 | US20080076753 Substituted spiroheterocycles |
| 03/27/2008 | US20080076752 substituted structure of 3-amino-2-(2,5-difluorophenyl)-2,3-dihydro-1,5-benzothiazepin-4(5H)-one; 6-amino-7-phenyl-1,4-thiazepan-5-one; -amino-2-phenyl-2,3-dihydro-1,5-benzoxazepin-4(5H)-one for treating neurological disorders such as Alzheimer's; inhibit the production of amyloid beta protein |
| 03/27/2008 | US20080076751 Azetidinone Derivatives and Methods of Use Thereof |
| 03/27/2008 | US20080076750 Azetidinone Derivatives and Methods of Use Thereof |
| 03/27/2008 | US20080076733 novel synthetic thiolatocobalamin; protects animal cells against oxidative stress damage; dietary supplement; also with vitamin B6 and a folate; cardiovascular disease, cerebrovascular disease, peripheral vascular disease, glaucoma, Alzheimer's disease, and dementia |
| 03/27/2008 | US20080076718 oligopeptide or polypeptide amino acid sequences as biodrug antitumor agents, anticarcinogenic agents; treating autoimmune diseases, AIDS, inflammatory diseases, cardiovascular disorder of ischemic processes, allograft rejection, cerebral strokes, traumas, burns, Alzheimer's disease, Parkinson's disease |
| 03/27/2008 | US20080076714 oral or mucosal administration for treating immune-mediated disorders such as allergies, auto-immune disease, transplantation-related disease and other inflammatory diseases; drug delivery method |
| 03/27/2008 | US20080076136 Nucleotide sequences coding transport protein for use in identifying modulators for treatment of pain; flavor enhancement |
| 03/27/2008 | US20080075789 Genes differentially expressed in bipolar disorder and/or schizophrenia |
| 03/27/2008 | US20080075781 Making oral dosage form by forming granules comprising oxycodone hydrochloride, alkyl cellulose and polymethacrylate, and drying said granules; improving efficiency and quality of pain management |
| 03/27/2008 | US20080075774 Treatment and/or prevention of a condition major depressive disorder and nicotine addiction; fewer incidences of and/or reduced severity of seizures associated with the administration of bupropion, as compared to known bupropion compositions |
| 03/27/2008 | US20080075771 Opioid antagonist is released in an amount that reduces effectiveness of opioid when dosage form is crushed; monolithic solidified oral dosage form; hydrophilic polymer such as alkyl cellulose or (meth)acrylic acid (co)polymer; drug delivery; resistant to dissolution in aqueous solutions of ethanol |
| 03/27/2008 | US20080075770 Monolithic solidified oral dosage form comprising a drug such as an opioid and a hydrophilic polymer such as alkyl cellulose or (meth)acrylic acid (co)polymer; dissolution resistant in aqueous solutions of ethanol; drug delivery |
| 03/27/2008 | US20080075768 Opioid antagonist is released to reduce effectiveness of opioid (hydromorphone) when dosage form is crushed; monolithic solidified oral dosage form; hydrophilic polymer such as alkyl cellulose or (meth)acrylic acid (co)polymer; drug delivery; resistant to dissolution in aqueous solutions of ethanol |
| 03/27/2008 | US20080075767 Ibuprofen-containing liquid filled hard capsules |
| 03/27/2008 | US20080075729 ras-mediated; administering immunosuppressive for immune constituents that may interfere with the systemic delivery of the reovirus; antiproliferative; in the neoplastic cells phosphorylation of PKR is prevented by inactivation or deletion of PKR; antitumor agents |
| 03/27/2008 | US20080075728 Combination Therapies Of Hmgb And Complement Inhibitors Against Inflammation |
| 03/27/2008 | US20080075727 Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies |
| 03/27/2008 | US20080075713 isomerase enzymes and ATP-binding cassette (ABC) transport proteins, used for controlling metabolism of triglycerides; diagnosis, prevention and treatment of metabolic disorders |
| 03/27/2008 | DE102006045803A1 Verwendung von Theanin zur Herstellung eines Arzneimittels zur Prophylaxe und Behandlung von psychiatrischen Störungen des zentralen Nervensystems, insbesondere von Depressionen und Schmerzen Use of theanine for the preparation of a medicament for the prophylaxis and treatment of psychiatric disorders of the central nervous system, especially depression and pain |
| 03/27/2008 | DE102006044694A1 Perorale feste Schmerzmittelzubereitung Peroral solid analgesic formulation |
| 03/27/2008 | CA2664099A1 Methods and compositions for treating amyotrophic lateral sclerosis (als) |
| 03/27/2008 | CA2664098A1 Compounds and method for treating canine cognitive dysfunction syndrome |
| 03/27/2008 | CA2663545A1 Neuroprotective peptide inhibitors of ap-1 signaling and uses thereof |
| 03/27/2008 | CA2663347A1 Ppar mediated modulation of neurogenesis |
| 03/27/2008 | CA2663272A1 Composition for the treatment of amyotrophic lateral sclerosis |
| 03/27/2008 | CA2663269A1 Combination of nmda-receptor ligand and a compound with 5-ht6 receptor affinity |
| 03/27/2008 | CA2663240A1 4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]diazepine derivatives |
| 03/27/2008 | CA2663057A1 N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| 03/27/2008 | CA2662848A1 2-aryl-6-phenylimidazo[1,2-.alpha.]pyridine derivatives, preparation thereof and therapeutic use thereof |
| 03/27/2008 | CA2662773A1 N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| 03/27/2008 | CA2662484A1 Sulfonylpyrazole and sulfonylpyrazoline carboxamidine derivatives as 5-ht6 antagonists |
| 03/26/2008 | EP1903045A1 Pyrazolopyrimidine derivative |
| 03/26/2008 | EP1903033A1 Coniosetine, process for preparation and use as pharmaceutical |
| 03/26/2008 | EP1903028A1 Conjugates of glutamate and NMDA receptor channel blockers without excito-toxic effects |
| 03/26/2008 | EP1902733A1 Combination of a NMDA-receptor ligand and a compound with 5-HT6 receptor affinity |
| 03/26/2008 | EP1902729A1 Int6 PROTEIN INVOLVED IN HYPOXIA STRESS INDUCTION AND USE THEREOF |
| 03/26/2008 | EP1902716A1 Prophylactic and/or therapeutic agent for motor disorder |
| 03/26/2008 | EP1902715A2 Use of paliperidone for the treatment of psychiatric patients with reduced hepatic function |
| 03/26/2008 | EP1902714A1 Prodrugs of gaba analogs, compositions and uses thereof |
| 03/26/2008 | EP1902710A1 Pharmaceutical composition and beverage composition comprising l-arginine |
| 03/26/2008 | EP1902068A1 Egfr inhibitors promote axon regeneration |
| 03/26/2008 | EP1902057A1 Macrocyclic heterocyclic aspartyl protease inhibitors |
| 03/26/2008 | EP1902055A1 Pyridazine compounds as glycogen synthase kinase 3 inhibitors |
| 03/26/2008 | EP1902044A1 5-htx modulators |
| 03/26/2008 | EP1902041A1 New compounds, process for their preparation, intermediates, pharmaceutical compositions and their use in the treatment of 5-ht6 mediated disorders such as alzheimer s desease, cognitive disorders, cognitive impairment associated with schizophrenia, obesity and parkinson's disease |
| 03/26/2008 | EP1901769A2 Use of cytokine-derived peptides in treatment of pain and neurodegenerative disease |
| 03/26/2008 | EP1901765A1 Intralesional treatment of psoriasis |
| 03/26/2008 | EP1901753A1 Multiple sclerosis therapy and diagnosis |